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Abstract
Background: Osteoprotegerin (OPG) and von Willebrand factor (VWF) form complex within endothelial cells and
following secretion. The nature of blood group antigens strongly influences the levels of circulating VWF, but there
is no available data concerning its ascendancy on OPG levels. We aimed to assess the relationship of AB0 blood
groups with OPG, VWF levels (VWF: Ag) and collagen binding activity (VWF: CB) in peripheral arterial disease (PAD)
patients.
Methods: Functional and laboratory parameters of 105 PAD patients and 109 controls were examined. Results of
OPG, VWF: Ag, VWF: CB (ELISA-s) were analysed by comparative statistics, together with clinical data.
Results: OPG levels were higher in patients than in controls (4.64 ng/mL vs. 3.68 ng/mL, p < 0.001). Among patients
elevation was marked in the presence of critical limb ischemia (5.19 ng/mL vs. 4.20 ng/mL, p = 0.011). The OPG in
patients correlated positively with VWF: Ag and VWF: CB (r = 0.26, p = 0.008; r = 0.33, p = 0.001) and negatively with
ankle-brachial pressure index (r = -0.22, p = 0.023). Furthermore, OPG was significantly elevated in non-0 blood
groups compared to 0-groups both in patients and controls (4.95 ng/mL vs. 3.90 ng/mL, p = 0.012 and 4.09 ng/mL
vs. 3.40 ng/mL, p = 0.002).
Conclusions: OPG levels are associated to blood group phenotypes and higher in non-0 individuals. Increased OPG
levels in PAD characterize disease severity. The significant correlation between OPG and VWF:CB might have
functional importance in an atherothrombosis-prone biological environment.
Keywords: Osteoprotegerin, Von Willebrand factor, Peripheral arterial disease, Endothelial dysfunction, AB0 blood groups,
Atherosclerosis, Atherosclerosis, Critical ischemia, Hypertension, Diabetes
Background
Peripheral arterial disease (PAD) is an occlusive mani-
festation of atherosclerosis involving most frequently the
limbs. Persons with an increased risk are primarily the
elderly, smokers, and patients with diabetes, hyperten-
sion and dyslipidaemia. The third important clinical
manifestation of atherosclerosis presents significant
clinical overlap with coronary artery disease (CAD) and
carotid stenosis [1, 2]. Intermittent claudication is the
leading symptom of PAD and a 10 year follow-up inves-
tigative branch of Framingham study showed that it has
the lowest occurrence rate in individuals with blood
group 0 [3].
Endothelial dysfunction is an early and important
trigger of atherogenesis, emerging as a response to a
number of various oxidative, infectious and mechanical
injuries. Von Willebrand factor (VWF) and osteopro-
tegerin (OPG) are markers of these processes [4, 5].
VWF, a large multimeric glycoprotein that adheres
to sub-endothelial collagen in order to catch bound
platelets at high shear- and elongation forces [6]. Os-
teoprotegerin (OPG) is a dimeric glycoprotein with a
multifunctional cytokine role and highly expressed in
a large number of tissues [7]. They are associated in
plasma, co-localized in, and co-secreted from the
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Weibel-Palade bodies of the endothelial cells [8, 9].
The up-regulation of OPG in severe forms of periph-
eral arterial disease has been described [10].
There is evidence that AB0 blood type is a major de-
terminant of VWF [11-13] VWF level and activity were
lower in 00, A0, B0, A20, A30 and rare genotypes than in
AA, BB, and AB [14]. The relationship between circulat-
ing OPG levels and AB0 blood groups has never been
analysed. Little is known about the potential action of
glycosyltransferases A and B on OPG levels, the effects
of glycosylation sites D178 and D183 on the formation
of disulphide bonds, the correct folding of the molecule
and how OPG glycosylation could interfere with de-
gradative pathways [15–17].
Our hypothesis is, that AB0 blood group type is de-
terminant of OPG levels in blood, similar to its role
on VWF.
The aim of our observational study was to investigate
the association of OPG and PAD along with VWF level
(VWF: Ag) and collagen binding activity (VWF: CB) in
an AB0 group dependent manner. To achieve our target,
we performed measurement of serum and plasma OPG,
VWF: Ag and VWF: CB along with AB0 blood group
determination; then we analysed the relationship be-
tween those parameters in PAD patient and control
groups; we then analysed their clinical and biochemical
correlations. Since some studies have measured OPG
from sera, while others focus on the plasma fraction
[18, 19] and as the sample for VWF is plasma, we
compared OPG results from serum and plasma too in
order to test the relevance of OPG in this aspect.
Methods
Patients, diagnosis, risk factors and comorbidities
One hundred fifteen patients – previously diagnosed
with various stages of PAD- were selected for this study.
After excluding 10 patients with malignancies, acute in-
flammatory disorders, infections, or autoimmune vascular
disease, 84 males and 21 females (age 64.5 ± 0.98 years)
remained. The control group consisted of 109 individuals
(75 males, 34 females, age 57 ± 1.34 years), selected from
the National Health Care Survey, Romania. Before admis-
sion, written consignment was obtained from each patient;
the study was approved by the ethics committee of
the Clinical Emergency Hospital of Târgu-Mureș and
was carried out in accordance with the Declaration of
Helsinki for experiments involving humans.
Diagnosis of PAD was stated on medical history, clin-
ical examination and measurement of the ankle-brachial
pressure index (ABI) and Duplex ultrasonography. For
calculation of the ABI, systolic blood pressure measure-
ments were performed on the brachial, dorsalis pedis,
and posterior tibial arteries bilaterally. The higher ankle
pressure of the dorsalis pedis artery and the posterior
tibial artery measurements for each limb were divided
by the higher of the two brachial values. Both the
lower and the mean of the two indexes were used for
statistical comparison.
Intermittent claudication was assessed using the Walk-
ing Impairment Questionnaire. Stages III and IV, the
presence of rest pain and/or ulceration associated
with an ankle systolic pressure of ≤50 Hgmm were
considered as critical leg ischemia.
Coronary artery disease was assumed to be present in
patients with clinical history of angina pectoris or docu-
mented myocardial infarction (MI), previous positive
coronary angiography or angioplasty, and/or resting
ECG changes suggestive for ischemia: ST-segment de-
pression, Q-wave changes or T-wave changes, according
to the Minnesota coding method.
A Colour Duplex carotid artery scan was performed
using a GE Agilent Image Point HXB.1 Sonos 4500/
5500B.1 ultrasound system. B-mode, colour- and pulsed-
wave Doppler analyses were performed on both sides to
identify arterial wall lesions and stenosis (expressed as
the percentage decrease in artery diameter). Where no
plaques were identified, carotid intima-media thickness
(CIMT) was measured bilaterally at the far wall of the
distal common carotid artery, immediately proximal to
bifurcation, in the end diastole. Carotid artery athero-
sclerosis was defined as CIMT > 1.00 mm, or the pres-
ence of plaques at any levels.
The risk factors evaluated in this study included
diabetes mellitus, hypertension, haemostatic, lipid and
inflammatory factors. Hypertension was diagnosed ac-
cording to JNC 7 protocols. Diabetes mellitus was de-
fined as fasting glucose >6.94 mmol/L on at least two
measurements, or evidence for current use of insulin
or oral hypoglycaemic medication.
Laboratory analysis
Blood samples were taken after overnight fasting into
vacutainers with either no additive or 3.2 % trisodium
citrate (Becton-Dickinson Vacutainer Systems, UK).
Centrifugation was performed at 3000 rpm for 10 min,
after which the serum and plasma aliquots were sepa-
rated, submitted to routine biochemistry or deep-frozen
at −70 °C. Serum fasting glucose, total cholesterol, high-
density cholesterol and triglycerides were determined by
enzymatic methods on an ABBOTT AEROSET auto-
mated biochemistry analyser (Abbott Diagnostics, USA).
High-sensitivity CRP (hs CRP) was measured on a
COBAS INTEGRA 400 analyser by an immunoturbidi-
metric method (Roche Diagnostics, Switzerland). Plasma
fibrinogen was determined according to the Clauss
method with Fibrinogen Reagent (Technoclone, Austria)
and Behnk Thrombotimer (Germany). AB0 blood group
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antigens were determined by the direct Beth-Vincent
method with anti-A, anti-B, anti-AB sera (DiaClon AB0,
Bio-Rad Laboratories, Switzerland).
VWF: Ag was measured by ELISA according to a pre-
viously established protocol [20], VWF: CB was mea-
sured as Ag, but type III collagen (Sigma, USA) was
used for coating high binding capacity plate (Greiner
Bio-One, Austria). Infiniti 200 M (Tecan Trading AG,
Männedorf, Switzerland) was used for optical reading
and its Magellan software for data processing. All
samples were determined in duplicate and calculations
were based on four-parameter Marquardt standard
curve fitting. A standard was purchased from Siemens,
Germany, and results were expressed as %.
OPG levels were determined both from serum and
plasma using the R&D Systems DuoSet ELISA kit
(DY805, R&D Systems Europe, UK), according to the
manufacturer’s instructions. Recombinant human OPG
(Part No. 840371; R&D Systems) served as standard, and
concentrations were expressed as ng/mL. There are con-
troversial results with regards to the relation of OPG
serum and plasma levels in the literature. Different anti-
coagulants, clot activator, anti-proteases, time between-
collection, centrifugation and storage cause the main
variations [18, 19]. Bland-Altman analysis did not reveal
difference between our serum and plasma based OPG
measurements (n = 181, bias = 0.055, SD = 0.39), for this
reason we used the plasma values for further statistical
analysis. Intra-observer coefficient of variation for OPG,
VWF: Ag and VWF: CB, the outcome parameters were
below 11, 10 and 12 %, respectively.
Statistical analysis
We used the IBM SPSS Statistics for Windows, Version
19.0 (IBM Corp., Armonk, NY, USA) and GraphPad
Prism 6 (GraphPad Software Inc., USA) for the statistical
calculations. Since the main parameters, OPG and VWF
had a non-Gaussian distribution, we applied non-
parametric statistical tests in our evaluation. The
Kruskal-Wallis ANOVA was used for multiple group
comparison; paired contrasts were carried out using the
Mann-Whitney U test. Fisher’s exact test was applied to
compare 2×2 or larger between-group distributions of
discrete parameters. All correlations were performed by
the Spearman rank-correlation test. Multiple linear
regression models were applied to define the effect of
clinical and laboratory variables on ln-transformed
OPG levels.
Results
The main characteristics of the patients and control
groups
First we show the clinical features followed by the bio-
chemical characteristics of the patient and the control
groups in Tables 1, labelling the results of the statistical
comparisons.
The distribution of genders, incidence of diabetes,
history of stroke and MI and the rate of 0/non-0 blood
groups revealed no different between patients and con-
trols. The age was higher; hypertension, CAD, multiple
atherosclerotic involvement, antihypertensive, anticoagu-
lant and statin usage were more frequent in the PAD
Table 1 The main clinical and laboratory parameters of the
patient and control groups
Parameters Patients
(n = 105)
Controls
(n = 109)
Age *** 64.2 ± 0.98 57.0 ± 1.34
Gender (male) 84 (80) 75 (69)
Diabetes 32 (30.5) 23 (21.1)
Hypertension *** 92 (87.6) 44 (40.4)
Stroke history 12 (11.4) 6 (5.5)
Myocardial infarction history 11 (10.4) 18 (16.5)
CAD*** 72 (68.6) 40 (36.7)
Intermittent claudication 105 (100) no
Critical limb ischemia 30 (28.6) no
Significant carotid stenosis a 10 (13.5) nd
Multiple atherosclerotic
involvement***
21 (20) 4 (3.7)
Haemorheological treatment 105 (100) no
Antihypertensives *** 87 (82.8) 29 (26.6)
Anticoagulants ** 25 (23.8) 10 (9.2)
Statins *** 73 (69.5) 10 (9.2)
Fibrates 10 (9.5) 4 (3.7)
Rate of AB0 blood groups
(0/non-0)
0.38 0.49
ABI (lower) 0.48 (0.36–0.60) nd
ABI (mean) 0.59 (0.43–0.73) nd
CIMT (lower) a 1.00 (0.70–1.30) nd
CIMT (mean) a 1.25 (0.7–1.45) nd
OPG [ng/mL] *** 4.64 (3.49–6.54) 3.68 (2.92–4.81)
VWF:Ag [%] 129 (96–174) 116 (94–150)
VWF:CB [%] * 123 (94–163) 107 (88–136)
Fibrinogen [g/L] *** 4.10 (3.04–5.03) 3.00 (2.32–3.50)
Total cholesterol [mmol/L] 4.83 (3.98–5.87) 5.10 (4.29–5.88)
HDL–cholesterol [mmol/L] *** 1.19 (1.03–1.40) 1.52 (1.28–1.74)
Triglycerides [mmol/L] 1.33 (0.96–1.76) 1.20 (0.86–1.74)
CRP [mg/L] 5.03 (2.22–9.67) 4.44 (1.84–6.55)
Age is expressed as mean ± SE, gender as the number of males and their
percentage, disease states as number and percentage in brackets, compared
to all individuals of the group, parameters are given as median with quartile
range in brackets. * p < 0.05, ** p < 0.01, *** p < 0.001 significances of patients
to control (Mann–Whitney U test for continuous variables and Fisher’s exact
test for categorical variables), aexamined in 74 cases, no = no sign or history at
controls, nd = not determined
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group. ABI and CIMT were measured for diagnostic and
staging purposes during hospitalization of PAD patients.
Results of the biochemical tests show that OPG levels
[ng/mL] and VWF: CB [%] were significantly higher in
patients than in controls (4.64 vs. 3.68, p < 0.001, and
123 vs. 107, p = 0.03). On the whole population, the
relative risk of having PAD in the upper OPG quar-
tile vs. the lower quartile was 1.75 (95 % CI: 1.17–2.60,
p = 0.006). Fibrinogen levels were also significantly in-
creased, while HDL-cholesterol levels were decreased in
patients compared to controls, see Table 1.
Correlations of OPG and the main clinical and laboratory
parameters
OPG proved to be dependent on age (r = 0.36, p < 0.001)
but independent of gender: 4.02 (3.09–5.55) in males vs.
4.45 (3.48–6.55) in females (p = 0.093). Diabetic patients
showed higher OPG values than non-diabetics with a bor-
derline significance, 4.83 (4.09–7.80) vs. 4.48 (3.30–6.26),
p = 0.052. OPG levels were significantly elevated in
the whole population (patients and controls) with
hypertension (p < 0.001), previous stroke (p = 0.005),
CAD (p = 0.037), anti-hypertensive (p < 0.001) and
fibrate (p = 0.033) users. OPG levels were elevated but
not significantly in MI history positive individuals,
anticoagulant and statin receivers. Among patients,
those with critical limb ischemia (n = 30) had a signifi-
cantly higher OPG and VWF: CB, than the rest of the
group (5.19 vs. 4.20, p = 0.011, and 138 vs. 116, p = 0.031).
In patients OPG showed significant negative correlations
with the mean and lower ABI values (r= -0.22, p = 0.023
and r = -0.21, p = 0.032). OPG was unrelated to CIMT ob-
tained on patients with no significant carotid stenosis
(data not shown).
OPG correlated positively with VWF: Ag and VWF:
CB (r = 0.26, p = 0.008; r = 0.33, p = 0.001, respectively)
in patients and also in controls (OPG-VWF: Ag r = 0.25,
p = 0.008, OPG-VWF: CB r = 0.26, p = 0.005). Figure 1a
and b show the correlation and linear regression line
with 95 % confidence intervals for correlation of OPG
and VWF: CB in patients and in controls. There was no
significant relationship between OPG, fibrinogen, total
and HDL-cholesterol, triglycerides and CRP levels.
We did not test the effect of smoking on OPG, as at
the time of admission no patients were active smokers.
Clinical and laboratory parameters of zero- and non-zero
blood group patients and controls
Comparison of clinical and laboratory parameters for 0-
and non-0 blood group patients and controls is given in
Additional file 1: Table S1. Age, distribution of genders,
incidence of diabetes, hypertension, stroke history, CAD,
critical limb ischemia, carotid stenosis were not signifi-
cantly different between groups. History of previous MI
was assessed significantly more often in the non-0
group. The positive history for MI was significantly re-
lated to the presence of the non-0 blood groups: all 11
patients and 16 controls from 18 with a previous MI had
an A, B or AB phenotype (difference in proportions p =
0.002 for the overall population and = 0.031 for both pa-
tients and controls). Intima-media thickness showed a
mild, but non-significant increase in the 0 compared to
non-0 group, the frequency of carotid stenosis in the two
groups was similar. CIMT and ABI values, fibrinogen, total
serum cholesterol, HDL-cholesterol, triglycerides, CRP
levels showed no difference.
Comparison of Non-0 and 0 patients presented sig-
nificantly higher OPG (4.95 vs. 3.90, p = 0.012), VWF:
Ag (137 vs. 102, p < 0.001) and VWF: CB (134 vs. 94,
p < 0.001), as shown in Fig. 2. These findings were
also characteristic of controls, as follows: OPG (4.09 vs.
3.40, p = 0.002), VWF: Ag (132 vs. 98, p < 0.001), VWF: CB
(117 vs. 93, p < 0.001).
Moreover, we observed that the nature of blood
groups markedly influenced the OPG-VWF: CB correl-
ation. In the 65 patients and controls with group 0, the
correlation was absent (r = 0.017, p = 0.891). In non-0
patients and controls (n = 149), OPG correlated signifi-
cantly with VWF: CB (r = 0.28, p < 0.001).
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Fig. 1 Correlation between plasma OPG levels and VWF: CB activities. a Correlation of OPG with VWF: CB in patients. b Correlation of OPG with
VWF: CB in controls. Mean ± 95 % confidence intervals are shown by the regression- and the dotted lines
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Association between circulating OPG and ABzero blood
groups
A number of 29 blood group 0 patients had been regis-
tered (27.6 %), while the non-0 group had the following
composition: 46 group A (43.8 %), 18 group B (17.1 %),
12 group AB (11.4 %) see Additional file 2: Table S2.
Among controls, the distribution of AB0 phenotypes
was as follows: 36 (33 %) group 0, 32 (29.3 %) group A,
29 (26.6 %) group B, 12 (11 %) group AB. The OPG
VWF levels and collagen binding activity by individual
blood groups are detailed in Additional file 2: Table S2.
OPG showed the highest levels at blood group AB in
patients and at group A in controls, while VWF: Ag and
CB were highest in group B and AB, respectively.
Due to the relatively small number of patients and
controls included in each blood group, we weighed the
effect of AB0 groups as 0- and non-0.
Multiple linear regression model for high OPG levels
On the basis of the aforementioned results we set up a
multiple linear regression model for the determinants of
high OPG values Table 2. The regression model describes
the ln-transformed OPG levels as a dependent variable in
the whole studied population, and contains gender, age,
diagnosis of PAD, stroke history, ln-transformed VWF:
CB and 0/non-0 blood group categories. VWF: CB, PAD,
AB0 categories remained significantly associated with the
OPG levels after adjustment for diabetes, hypertension,
MI, CAD, anti-hypertensive, anti-coagulant drugs, statin
and fibrate usage.
Despite the strong association with the non-0 blood
groups, a positive history for MI did not prove to be a
significant determinant of OPG levels.
Discussion
The biological consequence of elevated OPG remains a
subject of debate, while it is has been shown for several
years that the circulating OPG concentration correlates
with the severity of atherosclerotic conditions [7]. Al-
though the higher prevalence of PAD among non-0
blood group carriers has been recognized for a long time
[21], association of OPG and AB0 blood groups has not
been analysed until our present study.
In our design, known peripheral arterial disease pa-
tients were selected with a high frequency of multiple
atherosclerotic involvement and comorbidities, such as
hypertension and diabetes. The clinical and laboratory
characteristics of this group were compared to a control
group. Diabetes, hypertension, stroke history, myocardial
infarction history and CAD occurred also in the control
group that in contrast, did not express PAD.
Considering the mean ABI values, our patient group
had advanced forms of atherosclerosis. OPG values
showed significant negative correlation with the mean
and lower ABI, which are measures of PAD severity.
Corroborating previous results, we observed significantly
higher values of OPG in patients compared to individ-
uals without PAD [22–24]. The association of OPG with
PAD is still controversial, since some authors have failed
to prove it [25, 26].
We also elucidated a higher OPG in sufferers of crit-
ical limb ischemia and a negative correlation with the
ABI scores. In the study of Ziegler et al., plasma OPG
correlated with the ABI, however, the authors found no
significant increase in patients compared to controls. It
should be noted that they did not determine the AB0
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Fig. 2 Plasma OPG, VWF: Ag levels and VWF:CB activity in patients and controls. Column scatter plot graph of the OPG and VWF values in patients
(a) and controls (b) according to 0 and non-0 blood groups. Values represented as median with interquartile range. Significant differences marked with
* for p < 0.05, ** p < 0.01, *** p < 0.001
Table 2 Multiple linear regression model for ln-transformed
OPG levels in the overall study population
B SE of B p-value
Gender 0.219 0.065 <0.001
Age 0.007 0.002 0.002
Presence of PAD 0.168 0.057 0.004
Stroke history 0.216 0.101 0.034
VWF:CB 0.238 0.075 0.002
0/non-0 groups 0.156 0.064 0.016
R = 0.519, the adjusted R square of the model is 0.248, p < 0.001
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blood groups, which, in the cases of their 67 patients
and 94 controls, could have influenced the results. The
incidence of diabetes, hypertension, the level of plasma
fibrinogen, total and HDL-cholesterol were comparable
to the characteristics of our group [25]. Ali et al. docu-
mented the association between serum OPG and ABI
[22]. In this study, two separate cohorts were included:
one consisting of Afro-Americans and another of non-
Hispanian whites, predominantly women, with a 73–80 %
incidence of hypertension, high BMI values, but low
frequency of peripheral arterial disease (9 % overall).
There are some controversial results regarding the ef-
fect of diabetes and hyperglycaemic status on OPG
levels: absence of relationship with the glycaemia status
[27], significantly elevated OPG in diabetic nephropathy
and in Japanese men with diabetes type 2 [28], slightly
increased OPG values in gestational diabetes [29]. In our
observations, the accompanying diabetes had only a
borderline effect on OPG levels.
OPG has been defined as an important mediator of
vascular calcification and is influenced by the presence
of arterial hypertension [7, 30]. In our whole population
(but not in PAD patients) high OPG levels were associ-
ated with the presence of hypertension.
Our findings revealed an association between higher
OPG levels and CAD in the whole studied population,
which was not significant in the patients with the lead-
ing symptoms of PAD. A number of clinical studies
mention that OPG correlates to the presence and the
most important cardiovascular disease endpoints, such
as long-term mortality in CAD patients [31]. In our MI
history patients, OPG was higher but the difference did
not reach the threshold of statistical significance due to
the reduced number of individuals in the subgroup.
Acute coronary events were correlated with elevation of
circulating OPG, however, some studied failed to link
myocardial ischemia to high OPG [32]. CAD also causes
increased levels of OPG, however, in polyvascular dis-
ease with no acute myocardial events, this association
might be masked by the advanced peripheral involve-
ment and calcification. Patients with carotid stenosis
show variable OPG levels, with elevations especially
on diabetes type 2 backgrounds [33]. In our study,
the subgroup with considerable carotid stenosis
showed no higher OPG levels than the rest of the pa-
tients. This was also found in cases with a previous
stroke history. In both subgroups OPG proved to be
higher than in those without significant stenosis or
stroke, but due to their restricted size the difference
did not reach significance.
We observed positive correlations between OPG,
VWF: Ag and VWF: CB both in patients and controls.
This significant relationship has not been described be-
fore. In our setting the VWF: CB shows slightly stronger
association with OPG levels, than VWF: Ag. In endothe-
lial cells, OPG resides in the Weibel-Palade bodies,
together with VWF and P-selectin and is co-secreted in
complex with VWF [8]. Vinholt et al. recently developed
an ELISA to measure it in plasma and found that only a
small fraction of OPG circulates in complex, and this
amount cannot be related to the severity of coronary cal-
cification. This finding is important but does not rule
out the functional importance of OPG-VWF complexes
[34]. According to our results, the correlation of OPG
and VWF: CB activity is significant only in non-0 group
individuals. The number of individuals in 0 blood groups
is relatively small to result in a significant correlations. It
is not known if OPG has ABH antigenic structure. VWF
does have, but it is also not known if the A and B anti-
genic forms of it bind better OPG than H form. The
presence of non-0 blood groups might confer to carriers
an increased potential for atherothrombosis [13]. Re-
cently, further relationships of VWF and OPG were
given by Rutten et al., who measured the “active VWF”
fraction and highlighted that in 1026 first ST-segment
elevation myocardial infarction (STEMI) cases the
plasma medians of total VWF, “active VWF”, OPG and
the ratio of VWF to “a disintegrin and metalloproteinase
with a thrombospondin type 1 motif, member 13”
(ADAMTS-13) were at a significantly high risk for
STEMI. After adjustments of these, only the “active
VWF” remained significant. In this compilation out of
the Chinese, Scottish and Italian cohort: only the latter
displayed elevated OPG, and AB0 blood groups were not
determined [35].
The most important finding of our study is that we
evidenced a significant association of high OPG with
the non-0 blood groups in PAD patients and controls.
The A and AB blood group carriers presented the
highest OPG values both in patients and controls
(Additional file 1: Table S1). VWF: Ag and VWF: CB
levels showed similar differences in favour of non-0
groups. The correlation between VWF: CB and the
categories of AB0 group is noteworthy. Specifically
VWF: CB is sensitive for the size of the VWF multi-
mers [36], but we have not found any information
concerning the relation of VWF multimer distribution
and AB0 group.
The effects of blood group antigens on atherosclerosis
manifestations, disease progression and outcomes have
been extensively studied [12, 37]. The glycosylated resi-
dues present on VWF at position N1574 influence the
cleavage of the multimers by ADAMTS-13 [38].
Whether VWF glycosylation affects or not complex for-
mation between OPG and VWF is a question for further
study.
To our knowledge, we are the first to show the associ-
ation of circulating OPG levels with AB0 antigens. In
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addition, our results show a statistically strong difference
between the VWF: CB activity of 0 and non-0 group
patients.
Ziegler et al. suggest a decreased OPG clearance in PAD,
which seems feasible for the Fontaine III-IV stages [25]. In
the mirror of our results, we assume that non-0 blood
group carbohydrate antigens present on the molecule
might influence OPG levels, either by inhibition of protease
cleavage or by an enhanced co-secretion along VWF from a
triggered vessel-wall with endothelial dysfunction.
One of the limitation of our study was that the data
presented here are descriptive in nature and the ob-
served associations do not prove causal relationships.
The other limitation was the relatively restricted number
of patients enrolled, and the lack of AB0 genotyping
possibilities, which could offer a more exact assessment
of the correlations described. Although we found evi-
dence for the association of OPG with 0 and non-0
blood group, further studies are needed to confirm this
relationship in larger populations.
Conclusion
High OPG levels are characteristic of PAD, especially in
patients with critical limb ischemia. Our study brings
new data regarding the association of high OPG values
with non-0 AB0 blood groups in PAD patients. While
the relationship of high VWF with non-0 groups is well
characterized and thought to have a causal role in the
higher incidence of atherothrombotic events in compari-
son to 0 groups, we are the first to correlate high circu-
lating OPG with these determinants. It is also new that
VWF collagen binding activity is a strong predictor of
OPG levels and that the OPG-VWF correlation is AB0
phenotype dependent. We think VWF and OPG are
markers of endothelial perturbation or damage as a re-
sult of arterial disease. To elucidate whether elevated
OPG represents an increased prothrombotic potential
or, on the other hand, a protective, tackling actor in
peripheral arterial disease with high atherosclerotic
burden, needs further studies.
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